Sugi Predict

Sugi Predict / Compounds / SCHEMBL1531292

SCHEMBL1531292

SCHEMBL1531292

COC(=O)c1sc(-c2ccc(Cl)cc2)cc1N=CN(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.58
▸ KDM4E B2RXH2 6/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ NPC1 O15118 1/20 0.58
▸ CASP3 P42574 1/20 0.58
▸ SENP8 Q96LD8 1/20 0.58
▸ SENP7 Q9BQF6 1/20 0.58
▸ SENP6 Q9GZR1 1/20 0.58
▸ KMT2A Q03164 3/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.53
▸ TP53 P04637 1/20 0.47
▸ IKBKB O14920 2/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ POLB P06746 1/20 0.43
▸ MEN1 O00255 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ GFER P55789 1/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ PTPRA P18433 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1531291 1.00 MAPT (0.58) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL5255875 1.00 MAPT (0.58) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL12374411 0.89 MAPT (0.44) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL2309235 0.88 IKBKB (0.58) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL2309229 0.88 IKBKB (0.58) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL4725164 0.87 MAPT (0.48) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL14350084 0.87 MAPT (0.48) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL4439815 0.86 PTPN1 (0.48) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL6230519 0.86 PTPN1 (0.48) MAPTKDM4ERAB9ANPC1CASP3
SCHEMBL13118436 0.86 MAPT (0.58) MAPTKDM4ERAB9ANPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081670-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES BAXTER ANDREW 2010-04-01 — — US claimed
EP-1876179-B1 Thienopyrimidone compounds TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-1987042-B1 NOVEL AMINO ALCOHOL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI SA (FR) 2015-01-21 — — EP disclosed
US-8853208-B2 Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-10-07 — — US disclosed
US-8828991-B2 Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments SANOFI (FR) 2014-09-09 — — US disclosed
US-8618115-B2 Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them BRISTOL-MYERS SQUIBB COMPANY (US) 2013-12-31 — — US disclosed
EP-1948665-B1 THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2013-02-27 — — EP disclosed
US-7989445-B2 Thienopyrimidone compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-02 — — US disclosed
US-7989433-B2 Substituted thieno[3,2-D]pyrimidines as melanin concentrating hormone receptor-1 antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-02 — — US disclosed
EP-2310394-A1 HYDROXY SUBSTITUTED THIENO PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS Bristol-Myers Squibb Company (US) 2011-04-20 — — EP disclosed
EP-1442025-B1 PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 SMITHKLINE BEECHAM PLC (GB) 2007-03-07 — — EP disclosed
US-20060194871-A1 Heterocyclic mchr1 antagoists SMITHKLINE BEECHAM CORPORATION 2006-08-31 — — US disclosed
EP-1678184-A1 3-(4-AMINOPHENYL)THIENOPYRIMID-4-ONE DERIVATIVES AS MCH R1 ANTAGONISTS FOR THE TREATMENT OF OBESITY, DIABETES, DEPRESSION AND ANXIETY GLAXO GROUP LIMITED (GB) 2006-07-12 — — EP disclosed
EP-1618112-A1 HETEROCYCLIC MCHR1 ANTAGONISTS SmithKline Beecham Corporation (US) 2006-01-25 — — EP disclosed
WO-2005042541-A1 3-(4-AMINOPHENYL) THIENOPYRIMID-4-ONE DERIVATIVES AS MCH R1 ANTAGONISTS FOR THE TREATMENT OF OBESITY, DIABETES, DEPRESSION AND ANXIETY GLAXO GROUP LIMITED (GB) 2005-05-12 — — WO disclosed
WO-2004092181-A9 HETEROCYCLIC MCHR1 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2005-01-27 — — WO disclosed
US-20040220404-A1 Pyrimidinones as melanin concentrating hormone receptor 1 SMITHKLINE BEECHAM P.L.C. (GB) 2004-11-04 — — US disclosed
WO-2004092181-A1 HETEROCYCLIC MCHR1 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-10-28 — — WO disclosed
EP-1442025-A1 PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 SMITHKLINE BEECHAM PLC (GB) 2004-08-04 — — EP disclosed
WO-2003033476-A1 PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 SMITHKLINE BEECHAM PLC (GB) 2003-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220404-A1 Pyrimidinones as melanin concentrating hormone receptor 1 MC1R, MCHR1, MCHR2 MAPT 2954/4885KDM4E 4227/4885RAB9A 1491/4885
US-20100081670-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES CCL11, CCL2, CCR2 MAPT 3823/4885KDM4E 4510/4885RAB9A 1395/4885
US-20060194871-A1 Heterocyclic mchr1 antagoists MCHR1, MCHR2, MC1R MAPT 2683/4885KDM4E 2454/4885RAB9A 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.